After 3 initial monthly injections, current dosing intervals range from every 8 to 16 weeks in patients with wAMD and DME and every 8 to 12 weeks in patients with DR.

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

Overall, 2679 pregnancy-related deaths could have been prevented if the national rate was reduced to the lowest state rate.

HealthDay News — A senior government health researcher has announced his retirement, accusing the National Institutes of Health (NIH) of censoring his latest findings on ultra-processed food. Kevin ...

“Midafternoon dosing of inhaled beclomethasone dipropionate better improved nocturnal lung function and inflammatory biomarkers compared with the alternative dosage timings without additional adrenal ...

Poor communication contributed to 24% of safety incidents in 42 studies that examined its contribution along with other causes.

Seven recommendations developed, including use of floating immunoreactive trypsinogen cutoff over fixed cutoff.